Medical Therapy. Adverse Effects or Lack of Adverse Effects

Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants

Matthew F. Pizzuto, Matthew M. Laughon, Wesley M. JacksonUniversity of North Carolina at Chapel Hill.United States Expert Opinion on PharmacotherapyExpert Opin Pharmacother 2023; DOI: 10.1080/14656566.2023.2257598 AbstractIntroduction: Pulmonary hypertension (PH) is a complex condition that encompasses an array of underlying disease processes and affects a diverse population of infants, including those with congenital heart disease, congenital diaphragmatic hernia, […]

Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants Read More »

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit

Richard U. Garcia, Asaad Beshish, Arene Butto, Usama Kanaan, Kevin MaherEmory University School of Medicine and Children’s Healthcare of Atlanta.United States Pediatric CardiologyPediatr Cardiol 2023; DOI: 10.1007/s00246-023-03282-y AbstractObjective: Limited data exists regarding prostanoid (PGI2) use in critically ill patients with pulmonary hypertension. (PH) in the pediatric cardiac intensive care unit (CICU) setting.Materials and methods: Single center, retrospective study

Continuous Prostanoid Initiation in Severe Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit Read More »

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration

Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. VargheseTexas Children’s Hospital and Baylor College of Medicine.United States Frontiers in PediatricsFront Pediatr 2023; 11DOI: 10.3389/fped.2023.1275389 AbstractThis corrects the article DOI: 10.3389/fped.2023.1050508. CategoryClass I. Idiopathic Pulmonary HypertensionClass I. Heritable

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration Read More »

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients

Julia McSweeney, Elizabeth Colglazier, Jasmine Becerra, Brienne Leary, Kathleen Miller‐Reed, Stephen Walker, Katy Tillman, Melissa Magness, Michelle Ogawa, Whitney Bannon, Tisha Kivett, Emma O. Jackson, Anne Davis, Cathy Shepard, Susan Richards, Elise Whalen, Shannon Engstrand, Zachary Di Pasquale, Jean A. ConnorBoston Children’s Hospital and Harvard Medical School. UCSF Benioff Children’s Hospital. Children’s Hospital of Colorado.

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients Read More »

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center

Sulaima Albinni, Julian Heno, Imre Pavo, Erwin Kitzmueller, Manfred Marx, Ina Michel‑BehnkeMedical University of Vienna.Austria Paediatric DrugsPaediatr Drugs 2023; 25: 467-481DOI: 10.1007/s40272-023-00573-y AbstractBackground: Pulmonary hypertension (PH) is a severe hemodynamic condition with high morbidity and mortality. Approved targeted therapies are limited for pediatric subjects, and treatments are widely adopted from adult algorithms. Macitentan is a safe and effective drug used for adult PH,

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center Read More »

Retrospective on global pulmonary hypertension clinical trials: 1999-2021

Lu Zheng, Jun Tan, Yi Yan, Shang Wang, Ping Yuan, Cheng Wu, Yin-Tao Zhao, Hai-Bo Yang, Francesco Nappi, Adriano R. Tonelli, Lan Wang, Qing-Hua Hu, Rong JiangFirst Affiliated Hospital of Zhengzhou University. Yeda Hospital of Yantai. Shanghai Children’s Medical Center and National Children’s Medical Center. Shanghai Pulmonary Hospital and Tongji University. Naval Medical University. Centre

Retrospective on global pulmonary hypertension clinical trials: 1999-2021 Read More »

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy

Kimberley G. Miles Paul J. Critser, Patrick D. Evers, Michelle Cash, Melissa Magness, Elizabeth Geers Meredith O’Neil, Zhiqian Gao, Nicholas J. Ollberding, Russel HirschCincinnati Children’s Hospital Medical Center and Cincinnati College of Medicine. Oregon Health and Sciences University. United States Pulmonary CirculationPulm Circ 2023;DOI: 10.1002/pul2.12264 AbstractParenteral prostanoid therapy (PPT) can result in supranormal cardiac index (SCI;

Factors leading to supranormal cardiac index in pediatric pulmonary hypertension patients treated with parenteral prostanoid therapy Read More »

Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use

Jennifer E. Schramm, John C. Dykes, Rachel K. Hopper, Jeffrey A. Feinstein, David N. Rosenthal, Rebecca J. KamenyJohns Hopkins University School of Medicine. Stanford University School of Medicine.United States American Society for Artificial Internal Organs JournalASAIO J 2023; DOI: 10.1097/MAT.0000000000002023 AbstractPediatric precapillary pulmonary hypertension can develop in response to systemic atrial hypertension. Systemic atrial decompression following

Pulmonary Vasodilator Therapy in Pediatric Patients on Ventricular Assist Device Support: A Single-Center Experience and Proposal for Use Read More »

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial

Joseph Sullivan, Lieven Lagae, J. Helen Cross, Orrin Devinsky, Renzo Guerrini, Kelly G. Knupp, Linda Laux, Marina Nikanorova, Tilman Polster, Dinesh Talwar, Berten Ceulemans, Rima Nabbout, Gail M. Farfel, Bradley S. Galer, Arnaold R. Gammaitoni, Michael Lock, Anupam Agarwal, Ingrid E. Scheffer, The FAiRE DS Study GroupUniversity of California San Francisco. University of Leuven. Great

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial Read More »

The use of high dose octreotide in management of neonatal chylothorax: Review

M. A. AlhasoonUnaizah College of Medicine and Medical Sciences and Qassim University.Saudi Arabia Journal of Neonatal and Perinatal MedicineJ Neonatal Perinatal Med 2021; 14: 457-461DOI: 10.3233/NPM-200644 AbstractBackground: Being a rare condition, the incidence of chylothorax among neonates is low, but the mortality rate is high. In a dire effort to reduce the risk of death, octreotide treatment

The use of high dose octreotide in management of neonatal chylothorax: Review Read More »

Scroll to Top